Faruqi and Faruqui, LLP Logo
Share this page

Depomed, Inc. (DEPO)



Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Depomed, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Depomed, Inc. (“Depomed” or the “Company”) (NASDAQ:DEPO).

The investigation focuses on whether the Company and its executives violated federal securities laws by failing to disclose Company activities that might have led to an investigation by the regulatory government authorities regarding its opioid products.

Specifically, during an investor call held post-market on August 7, 2017, the Company announced that on July 28, 2017 the Company received a subpoena from the Department of Justice and the office of the Attorney General of Maryland regarding its commercialization practices for its opioid products, NUCYNTA and Lazand. The Company reported that it “will be incurring legal expenses in support of [its] responses which are reflected in [its] updated guidance.” On this news, the Company’s stock price has declined.

If you invested in Depomed stock or options between and would like to discuss your legal rights, please fill out the form below. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com. 

Request Information

Please tell us about yourself by completing the form and we will provide you with additional
information on how to join the Class Action at no cost to you.

  • Case:
    Depomed, Inc. (DEPO)

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330


Case Details


  • 08/08/2017

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.